
WST Stock Forecast & Price Target
WST Analyst Ratings
Bulls say
West Pharmaceutical Servs is well positioned by durable, broad-based demand for high-value products, with HVP components up 20% organically and reaching 53% of Q3 revenue, while GLP-1 HVP components grew well into the 30s% range and remained just under 12% of revenue. The company’s outlook is further supported by management’s confidence in Annex-1 upgrades contributing about 200 bps to annual organic growth through the end of the decade, plus a broad conversion runway across injectable biologics and a large international and U.S. opportunity set. Strong execution also shows up in Q3’s 39.7% gross margin and 25.3% adjusted operating margin, and a multiyear productivity plan, automation, and capacity optimization should help translate mix shift into stronger earnings growth.
Bears say
West Pharmaceutical Servs is facing a softer organic growth profile as West Vantage declined 6.6% organically and the CGM program continues to roll off, while the overlap of legacy-program declines and new-program ramps is likely to mute reported segment growth through 2027. Its exposure to GLP-1 demand also looks less durable, since a meaningful shift toward oral formulations could reduce future volume growth for cartridges and auto-injectors that rely on its elastomer components, even though GLP-1s are expected to represent roughly the mid-teens of FY25 revenue. In addition, customer de-stocking, geopolitical and tariff-related supply chain risk, product recall exposure, and the prospect of multiple compression create a weaker fundamental setup if growth or margins fail to reaccelerate.
This aggregate rating is based on analysts' research of West Pharmaceutical Services and is not a guaranteed prediction by Public.com or investment advice.
WST Analyst Forecast & Price Prediction
Start investing in WST
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About West Pharmaceutical Services (WST) Forecast
WST Analyst Forecast & Price Prediction
Start investing in WST
Order type
Buy in
Order amount
Est. shares
0 shares